The Starpharma Holdings Limited (ASX: SPL) share price is pushing higher on Monday.
In morning trade the dendrimer products developer’s shares are up 2% to $1.22 following an announcement.
What did Starpharma announce?
This morning Starpharma announced that pharma giant AstraZeneca has commenced a phase 1 clinical trial of AZD0466 and the first patient has been successfully dosed.
According to the release, the trial will recruit patients with a range of cancers and will be conducted at up to five US sites.
The development of AZD0466 is being progressed under a multi-product license. This means Starpharma is eligible to receive development, launch, and sales milestones of up to US$124 million. Furthermore, it will receive tiered royalties on net sales if the product reaches that stage.
The release advises that the first dose of AZD0466 administered in the phase 1 trial has triggered a milestone payment to Starpharma of US$3 million.
This could be the first of many based on AstraZeneca’s comments. It has described AZD0466 as having the potential to be a best-in-class agent in this field with a broad opportunity in solid and haematological tumours (blood cancers) due to its ability to target both Bcl2 and Bcl/xL1.
Bcl2 is a clinically validated oncology target. The Bcl2 inhibitor, venetoclax, was approved by the US FDA in 2016 and has estimated peak global sales projected to be between US$2 billion to US$3 billion.
Starpharma CEO, Dr Jackie Fairley, said: “It is really exciting to achieve this important milestone both for our collaboration with AstraZeneca and for Starpharma’s DEP platform.”
“This is our first partnered DEP product to enter the clinic, alongside our three internal DEP products, DEP docetaxel, DEP cabazitaxel and DEP irinotecan. AZD0466 is a great illustration of the benefits that can be created for novel agents using Starpharma’s DEP platform and we look forward to further updates as the trial progresses,” she added.
The post Why the Starpharma share price is pushing higher today appeared first on Motley Fool Australia.
Our Motley Fool experts have just released a brand new FREE report, detailing 5 dirt cheap shares that you can buy today.
One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…
Another is a diversified conglomerate trading near a 52-week low all while offering a 2.8% fully franked yield...
Plus 3 more cheap bets that could position you to profit over the next 12 months!
See for yourself now. Simply click the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.
- Man bets $221,666 on one ASX stock
- Top analysts name their top 3 ASX blue chip shares for 2019
- 3 quality dividend shares to boost your income
- NEW: Free report names top 3 ASX dividend shares to buy for 2019
- 5 Stocks for Potentially Building Wealth After 50
James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Starpharma Holdings Limited. The Motley Fool Australia has recommended Starpharma Holdings Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2019